Study Demonstrates Concern for Retained Blood Syndrome after Heart Surgery

ClearFlow Executives Comment on New Data Anaheim, CA – March 25, 2015—Cardiac anesthesia investigators from Germany presented data this week at the International Anesthesia Research Society’s (IARS) 2015 Annual Meeting and International Science Symposium in Honolulu, HI. Critical care specialists from Charité - Universitätsmedizin Berlin’s Department of Anesthesiology and Intensive Care Medicine presented clinical data from 6,909 patients. Results from the data revealed that more than 16% of the patients studied required surgical reinterventions to deal with complications related to Retained Blood Syndrome (RBS). Patients who required reinterventions were reported to have a statistically significant increase in mortality, longer ICU and hospital stays as well as higher … [Read more...]

ClearFlow Employees Make a Stand For Heart Health At The American Heart Association’s Annual Heart & Stroke Walk & 5K Run

aha

Anaheim, CA – March 10, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, rallied its employees, their families and loved ones this past weekend in the name of heart health awareness for the American Heart Association’s 34th Annual Heart & Stroke Walk & 5K Run starting and finishing at Angel Stadium of Anaheim. Most of ClearFlow’s growing organization was represented at the event, with employees and their families getting involved to raise money for the good cause. “While our day to day efforts specifically focus on improving outcomes of cardiovascular and cardiothoracic procedures,” said ClearFlow President & CEO, Paul Molloy. “Heart health, improved quality of life and healthier lifestyles overall are at the very core of our mission. It … [Read more...]

ClearFlow’s PleuraFlow System Exhibited at Association of Physician Assistants in Cardiovascular Surgery Meeting

Anaheim, CA – March 2, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the 34th annual Association of Physician Assistants in Cardiovascular Surgery (APACVS) meeting in Las Vegas. PleuraFlow will also be displayed at the Maquet Medical Systems USA booth through March 4th. Maquet is the exclusive distributor of ClearFlow’s PleuraFlow System in the USA. The PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting after heart surgery. “We understand the crucial role physician assistants play in the operating room during cardiovascular and cardiothoracic procedures,” said ClearFlow … [Read more...]

ClearFlow Exhibits PleuraFlow System at Society of Thoracic Surgeons Annual Meeting

logo-active-clearance-technology

Groundbreaking Device Designed to Prevent Retained Blood Syndrome Draws Crowds in San Diego   Anaheim, CA – January 26, 2015—ClearFlow Inc., a medical device company based in Anaheim, CA, is currently exhibiting its innovative PleuraFlow® Active Clearance Technology® System at the Society of Thoracic Surgeons (STS) 51st  Annual Meeting in San Diego. PleuraFlow will continue to be displayed at ClearFlow’s booth (#636) at STS today and tomorrow. ClearFlow’s PleuraFlow System uses a first of its kind technology to enable caregivers to proactively keep chest drainage tubes clear of blood clotting in the early hours after heart surgery. PleuraFlow’s appearance and display at STS follows on the heels of Maquet Medical Systems USA’s announcement last week that the … [Read more...]

Maquet Medical Systems USA Announces Exclusive US Distribution Agreement with ClearFlow for PleuraFlow® Active Clearance Technology® System

prnewswire

WAYNE, N.J., Jan. 23, 2015 /PRNewswire/ -- Maquet Medical Systems USA announced today an exclusive US distribution agreement with ClearFlow, Inc. for its innovative PleuraFlow® Active Clearance Technology® (ACT™) System. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery. Maquet's sales representatives in the United States will begin selling PleuraFlow ACT during the first quarter of 2015. PleuraFlow ACT received 510(k) regulatory clearance from the U.S. Food and Drug Administration in December 2010. In October 2014, ClearFlow announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® … [Read more...]

ClearFlow announces positive clinical trial results for the reduction of hospital complications after heart surgery

Washington, DC.—October 10, 2014—ClearFlow Inc., a medical device company based in Anaheim, CA, today announced positive results from the Prevention of Retained Blood Outcomes Using Active Clearance Technology trial, (PRO-ACT), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent retained blood complications. The PleuraFlow System enables caregivers to actively keep chest drainage tubes clear of clot in the early hours after heart surgery.   The PRO-ACT studied the efficacy of a protocol for actively clearing chest tubes of clotted blood to prevent retained blood complications. “Chest tube clogging is known to occur in over one-third of heart surgery patients in the early hours after heart surgery, and nearly one in … [Read more...]

Mark your calendar!

On Friday, October 10th investigators will report clinical trial results from the Prevention of Retained Blood Outcomes with Active Clearance Technology (PROACT) assessing the use of PleuraFlow to reduce Retained Blood Complications after Cardiac Surgery at FACTS-Care CVT 2014 in Washington, D.C. This is one of the largest studies to assess outcomes with Active Clearance Technology to reduce complications after heart surgery.   … [Read more...]

Results of PleuraFlow Clinical Studies to be Released At CVT

Anaheim, CA., Oct. 1, 2014 -- ClearFlow, Inc., a medical device company based in Anaheim, CA, announced that results from the PRO-ACT trial, (Prevention of Retained Blood Outcomes Using Active Clearance Technology), a clinical study evaluating the use of PleuraFlow® Active Clearance Technology™ System to prevent Retained Blood Complications (RBC) will be presented at the upcoming Cardiovascular-Thoracic (CVT) Critical Care meeting in Washington, D.C. next week. CVT is the scientific annual meeting of FACTS-Care (Foundation for the Advancement of CardioThoracic Surgical Care).  The foundation promotes coordination of all members of the cardiovascular surgery team to advance knowledge and expertise in caring for the critically ill cardiothoracic surgery patients. Specialists … [Read more...]

Surgeons Share Methods to Reduce Retained Blood Complications after Heart Surgery

PR_icon

Toronto, Canada—May 5, 2014—Distinguished physicians from leading cardiac surgery centers gathered at an Educational Symposium to share their experiences with a new-generation blood evacuation system for use following cardiothoracic surgical procedures. ClearFlow, Inc. hosted the Symposium at the recent American Association of Thoracic Surgeon’s meeting in Toronto, Canada, where their award-winning technology was on exhibit for over 2,400 cardiac surgeons and healthcare professionals. Marc Gillinov, MD, a surgeon from the Cleveland Clinic discussed the incidence and consequences of the complications that can result from the incomplete evacuation of blood from a patient’s chest after cardiac surgery. Louis Perrault, MD, from Montreal Heart Institute described the lack of best … [Read more...]

ClearFlow Appoints Senior Sales Executive to N.America Leadership Position

PR_icon

Anaheim, California. ClearFlow Inc., a venture-funded designer and manufacturer of PleuraFlow® Active Clearance Technology™, a new generation blood evacuation system for use following cardiothoracic surgical procedures is pleased to announce that Mr. Michael Cox has joined the Company as Vice President of Sales, North America. Michael has progressed through successful sales and marketing leadership roles in major cardiovascular device firms including Edwards Lifesciences and AtriCure, most recently leaving Austin, Texas based heart-valve manufacturer On-XLife Technologies, Inc. to join ClearFlow. “We are thrilled to strengthen our senior management team with a sales executive of Michael’s caliber and proficiency” said ClearFlow President & CEO, Mr. Paul Molloy. … [Read more...]

ClearFlow's PleuraFlow® Active Clearance Technology and many of its features are protected by a comprehensive family of both US and foreign patents and patent applications in major markets throughout the world, including Canada, Australia and the European Community. In the United States, PleuraFlow® products are protected by US Patent Nos. 7,854,728, 7,951,243, 8,246,752, 8,048,233, 8,388,759 and 8,702,662. The PleuraFlow® product is the first device of its kind to effectively and reproducibly clear obstructing material from chest tubes without compromising the sterile field, and thus patient recovery. It is the only FDA 510(k) cleared device of its kind for this indication. ClearFlow's patent portfolio has been tailored not only to protect this product, but also to provide protection around this new market segment thus presenting a barrier to entry for competing products.